Corrigendum to "Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC" [Cancer Treat. Rev. 104 (2022) 102350].

Friedlaender, Alex; Naidoo, Jarushka; Luigi Banna, Giuseppe; Metro, Giulio; Forde, Patrick; Addeo, Alfredo

Friedlaender, Alex; Naidoo, Jarushka; Luigi Banna, Giuseppe; Metro, Giulio; Forde, Patrick; Addeo, Alfredo.

Afiliação

Friedlaender A; Oncology Department, University Hospital of Geneva, Switzerland; Oncology Service, Clinique Générale Beaulieu, Geneva (CH), Switzerland.
Naidoo J; Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA.
Luigi Banna G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
Metro G; Medical Oncology, Santa Maria Della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
Forde P; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Addeo A; Oncology Department, University Hospital of Geneva, Switzerland. Electronic address: alfredo.addeo@hcuge.ch.

Cancer Treat Rev ; 104: 102358, 2022 Mar.

Article em En | MEDLINE | ID: mdl-35219091

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Treat Rev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google